Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2017 Oct 20;17(1):215–221. doi: 10.1158/1535-7163.MCT-17-0330

Figure 1. Serum drug concentrations for all patients treated in the 1.0-mg/kg cohort.

Figure 1

Figure 1 contains the serum concentration-time profiles of enavatuzumab (1.0 mg/kg) intravenously every 2 weeks (1 cycle = 4 weeks). The observed average maximum concentration after the 1st dose was 28.1 mcg/mL. Steady state serum concentrations appeared to be reached following the second dose, with average minimum concentrations of 4.3 mcg/mL.